Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Trial Profile

An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 16 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitolisant (Primary)
  • Indications Narcolepsy
  • Focus Expanded access; Therapeutic Use
  • Acronyms PEACE
  • Sponsors Harmony Biosciences
  • Most Recent Events

    • 16 Sep 2019 According to a Harmony Biosciences media release, data from this trial will be presented at the World Sleep 2019 meeting in Vancouver, Canada from September 20-25, 2019.
    • 22 Aug 2019 Status changed from recruiting to completed.
    • 04 Jun 2019 According to a Harmony Biosciences media release, data from this study will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (8-12 June 2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top